Proposed NIH Cuts Hit Bipartisan Opposition in Congress

Both Democrats and Republications criticize the Trump administration’s plan to cut funding for biomedical research.

Written byDiana Kwon
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, RON COGSWELL

The Trump administration’s proposed $5.8 billion slash to US National Institutes of Health (NIH) funding has, as many expected, encountered bipartisan opposition in Congress.

Congress makes the final decision about budgets, and representatives from both political parties have criticized the proposed cuts. The cuts could have “catastrophic results” for patients and researchers, Representative Nita Lowey (D-NY), the senior Democrat on the House Appropriations Committee, told The New York Times.

“I’m extremely concerned about the potential impact of the 18 percent cut,” Representative Tom Cole (R-OK), a Republican and chairman of the House Appropriations subcommittee responsible for the NIH told the New York Times. He added that “this committee and certainly me, personally, will be very hesitant” to support the proposal. Cole told STAT News that ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Diana is a freelance science journalist who covers the life sciences, health, and academic life. She’s a regular contributor to The Scientist and her work has appeared in several other publications, including Scientific American, Knowable, and Quanta. Diana was a former intern at The Scientist and she holds a master’s degree in neuroscience from McGill University. She’s currently based in Berlin, Germany.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies